These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488 [No Abstract] [Full Text] [Related]
25. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Kakimi K; Nakajima J; Wada H Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127 [TBL] [Abstract][Full Text] [Related]
26. [Non-small cell lung cancer: news from immunotherapy]. Reinmuth N; Heigener DF; Reck M Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674 [TBL] [Abstract][Full Text] [Related]
27. To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis. Khunger M; Calabrese C; Kontzias A; Velcheti V J Thorac Oncol; 2017 Sep; 12(9):e147-e149. PubMed ID: 28838717 [No Abstract] [Full Text] [Related]
32. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906 [TBL] [Abstract][Full Text] [Related]
33. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Santana-Davila R; Chow LQ Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785 [No Abstract] [Full Text] [Related]
34. [Role of chemo(radio)theray prior to surgery for stage IIIa non-small cell lung carcinoma (localized non-resectable tumor)]. Smit EF; van Mourik JC; Slotman BJ; Postmus PE Ned Tijdschr Geneeskd; 1999 Oct; 143(40):1992-6. PubMed ID: 10535055 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in resectable NSCLC: Answering the question or questioning the answer? Liu SY; Feng WN; Wu YL Cancer Cell; 2024 May; 42(5):727-731. PubMed ID: 38701791 [TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Yang J; Chen J; Wei J; Liu X; Cho WC Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430 [TBL] [Abstract][Full Text] [Related]
37. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role? Gardiner RE; Jahangeer S; Forde P; Ariffin AB; Bird B; Soden D; Hinchion J Cancer Metastasis Rev; 2015 Mar; 34(1):129-44. PubMed ID: 25726003 [TBL] [Abstract][Full Text] [Related]
38. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Pennell NA Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472 [TBL] [Abstract][Full Text] [Related]
39. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer]. Fu MJ; Zhou JY Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists. Kifjak D; Hochmair MJ; Krenbek D; Milos RI; Heidinger BH; Prayer F; Röhrich S; Watzenboeck ML; Oberndorfer F; Klikovits T; Aigner C; Sinn K; Hoda MA; Hoetzenecker K; Haug AR; Prosch H; Beer L Eur J Radiol; 2023 Apr; 161():110732. PubMed ID: 36804313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]